Histologic changes in three explanted native cardiac valves following use of fenfluramines

Cardiovascular Pathology

Volumn 8, Issue 5, 1999, Pages 245-253

  Steffee, Craig H ^a   Singh, Harsharan K ^a   Chitwood, W Randolph ^b  

^a EAST CAROLINA UNIVERSITY   (United States)

^b Cardiothoracic Surgery   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FENFLURAMINE; PHENTERMINE;

ADULT; ARTICLE; CASE REPORT; DRUG EFFECT; DRUG SCREENING; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MORBIDITY; OBESITY; PRIORITY JOURNAL; VALVULAR HEART DISEASE;

ADULT; AORTIC VALVE; APPETITE DEPRESSANTS; DEXFENFLURAMINE; DRUG COMBINATIONS; FEMALE; HEART VALVE DISEASES; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MITRAL VALVE; PHENTERMINE;

EID: 0032828620     PISSN: 10548807     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1054-8807(99)00019-8     Document Type: Article

References (28)

1. Connolly H.M., Crary J.L., McGoon M.D., Hensrud D.D., Edwards B.S., Edwards W.D., Schaff H.V. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 337:1997;581-588.
2. Graham D.J., Green L. Further cases of valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 337:1997;635.
3. Cannistra L. Valvular heart disease associated with dexfenfluramine. N Engl J Med. 337:1997;636.
4. Devereux R.B. Appetite suppressants and valvular heart disease. N Engl J Med. 339:1998;765-767.
5. Department of Health and Human Services Interim Public Health Recommendations, November 1997. MMWR. 46:1997;1061-1066.
6. Griffen L. Asymptomatic mitral and aortic valve disease is seen in half of the patients taking phen-fen. Arch Intern Med. 158:1998;102.
7. Hutchinson S.J., Tak T., Mummaneni M., Bankwala Z., Hanna L.F., Kawanishi D.T., Rahimtoola S.H., Chandraratna P.A.N. Morphological characteristics of the regurgitant mitral valve. Can J Cardiol. 11:1995;765-769.
8. Rasmussen S., Corya B.C., Glassman R.D. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 337:1997;1773.
9. Josefson D. U.S. journal finds lower risk from diet pills. BMJ. 315:1997;1329.
10. Khan M.A., Herzog C.A., St Peter J.V.et al. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite suppressant drugs. N Engl J Med. 339:1998;713-718.
11. Weissman N.J., Tighe J.F., Gottdiener J.S., Gwynne J.T. An assessment of heart valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. N Engl J Med. 339:1998;725-732.
12. Jick H., Vasilakis C., Weinrauch L.A., Meier C.R., Jick S.S., Derby L.E. A population-based study of appetite suppressant drugs and the risk of cardiac valve regurgitation. N Engl J Med. 339:1998;719-724.
13. Cannistra L.B., Cannistra A.J. Regression of multivalvular regurgitation after the cessation of fenfluramine and phentermine treatment. N Engl J Med. 339:1998;771.
14. Kurz X., Van Ermen A. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 337:1997;1772-1773.
15. Brenot F., Herve P., Petitpretz P., Parent F., Duroux P., Simonneau G. Primary pulmonary hypertension and fenfluramine use. Br Heart J. 70:1993;537-541.
16. Abenhaim L., Moride Y., Brenot F., Rich S., Benichou J., Kurz X., Higenbottam T., Oakley C., Wouters E., Aubier M., Simonneau Begaud B. Appetite suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med. 335:1996;609-616.
17. Mark E.J., Patalas E.D., Chang H.T., Evans R.J., Kessler S.C. Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine. N Engl J Med. 337:1997;602-606.
18. Fowles R.E., Cloward T.V., Yowell R.L. Endocardial fibrosis associated with fenfluramine-phentermine. N Engl J Med. 338:1998;1316.
19. Ross E.M., Roberts W.C. The carcinoid syndrome. Comparison of 21 necropsy subjects with carcinoid heart disease to 15 necropsy subjects without carcinoid heart disease Am J Med. 79:1985;339-354.
20. Pinder R.M., Brogden R.N., Sawyer P.R., Speight T.M., Avery G.S. Fenfluramine. A review of its pharmacological properties and therapeutic efficacy in obesity Drugs. 10:1975;241-323.
21. Redmon B., Raatz S., Bantle J.P. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 337:1997;1773-1774.
22. Robiolio P.A., Rigolin V.H., Wilson J.S., Harrison J.K., Sanders L.L., Bashore T.M., Feldman J.M. Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography Circulation. 92:1995;790-795.
23. Redfield M.M., Nicholson W.J., Edwards W.D., Tajik A.J. Valve disease associated with ergot alkaloid use. Echocardiographic and pathologic correlations Ann Intern Med. 117:1992;50-52.
24. Hauck A.J., Edwards W.D., Danielson G.K., Mullany C.J., Bresnahan D.R. Mitral and aortic valve disease associated with ergotamine therapy for migraine. Arch Pathol Lab Med. 114:1990;62-64.
25. Marcus R.H., Sareli P., Pocock W.A., Barlow J.B. The spectrum of severe rheumatic mitral valve disease in a developing country. Correlations among clinical presentation, surgical pathologic findings, and hemodynamic sequelae Ann Intern Med. 120:1994;177-183.
26. Olson L.J., Subramanian R., Ackermann D.M., Orszulak T.A., Edwards W.D. Surgical pathology of the mitral valve. A study of 712 cases spanning 21 years Mayo Clin Proc. 62:1987;22-34.
27. Dare A.J., Veinot J.P., Edwards W.D., Tazelaar H.D., Schaff H.V. New observations on the etiology of aortic valve disease. A surgical pathologic study of 236 cases from 1990 Hum Pathol. 24:1993;1330-1338.
28. Klein A.L., Burstow D.J., Tajik A.J.et al. Age-related prevalence of valvular regurgitation in normal subjects. A comprehensive color flow examination of 118 volunteers J Am Soc Echocardiogr. 3:1990;54-63.